Jeremiah D Johnson1, Joseph M Nessler2, Ryan D Horazdovsky1, Sandy Vang1, Avis J Thomas3, Scott B Marston1. 1. Department of Orthopaedic Surgery, Regions Hospital, St. Paul, Minnesota; Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, Minnesota. 2. Creighton University School of Medicine, Omaha, Nebraska. 3. HealthPartners Institute for Education and Research, Bloomington, Minnesota.
Abstract
BACKGROUND: Periprosthetic joint infection is the most common cause of readmissions after total joint arthroplasty (TJA). Intrawound vancomycin powder (VP) has reduced infection rates in spine surgery; however, there are no data regarding VP in primary TJA. METHODS: Thirty-four TJA patients received 2 g of VP intraoperatively to investigate VP's pharmacokinetics. Serum and wound concentrations were measured at multiple intervals over 24 hours after closure. RESULTS: All serum concentrations were subtherapeutic (<15μg/mL) and peaked 12 hours after closure (4.7μg/mL; standard deviation [SD], 3.2). Wound concentrations were 922 μg/mL (SD, 523) 3 hours after closure and 207 μg/mL (SD, 317) at 24 hours. VP had a half-life of 7.2 hours (95% confidence interval, 7.0-9.3) in TJA wounds. CONCLUSIONS: VP produced highly therapeutic intrawound concentrations while yielding low systemic levels in TJA. VP may serve as a safe adjunct in the prevention of periprosthetic joint infection.
BACKGROUND: Periprosthetic joint infection is the most common cause of readmissions after total joint arthroplasty (TJA). Intrawound vancomycin powder (VP) has reduced infection rates in spine surgery; however, there are no data regarding VP in primary TJA. METHODS: Thirty-four TJA patients received 2 g of VP intraoperatively to investigate VP's pharmacokinetics. Serum and wound concentrations were measured at multiple intervals over 24 hours after closure. RESULTS: All serum concentrations were subtherapeutic (<15μg/mL) and peaked 12 hours after closure (4.7μg/mL; standard deviation [SD], 3.2). Wound concentrations were 922 μg/mL (SD, 523) 3 hours after closure and 207 μg/mL (SD, 317) at 24 hours. VP had a half-life of 7.2 hours (95% confidence interval, 7.0-9.3) in TJA wounds. CONCLUSIONS:VP produced highly therapeutic intrawound concentrations while yielding low systemic levels in TJA. VP may serve as a safe adjunct in the prevention of periprosthetic joint infection.
Authors: Derek J Overstreet; Vajra S Badha; John M Heffernan; Erin P Childers; Rex C Moore; Brent L Vernon; Alex C McLaren Journal: Drug Deliv Transl Res Date: 2019-08 Impact factor: 4.617
Authors: Matthew D Budge; John A Koch; Jonathan B Mandell; Alex J Cappellini; Sara Orr; Samik Patel; Dongzhu Ma; Olivia Nourie; Kimberly M Brothers; Kenneth L Urish Journal: Antimicrob Comb Devices (2019) Date: 2020-11-23
Authors: Benjamin F Ricciardi; Gowrishankar Muthukrishnan; Elysia A Masters; Nathan Kaplan; John L Daiss; Edward M Schwarz Journal: J Orthop Res Date: 2020-01-31 Impact factor: 3.494
Authors: Murray T Wong; Sarup S Sridharan; Erin M Davison; Richard Ng; Nicholas M Desy Journal: Clin Orthop Relat Res Date: 2021-08-01 Impact factor: 4.755
Authors: Kelly Moore; Rebecca Wilson-van Os; Devendra H Dusane; Jacob R Brooks; Craig Delury; Sean S Aiken; Phillip A Laycock; Anne C Sullivan; Jeffrey F Granger; Matthew V Dipane; Edward J McPherson; Paul Stoodley Journal: Antibiotics (Basel) Date: 2021-03-08